A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

To join this study, doctors will first need to confirm you have Thyroid Eye Disease (TED) based on a common assessment method. You'll need to be at least 18 years old.

There are also some reasons why you might not be able to join. For example, if your eye condition has improved significantly on its own between your initial check-up and the start of the study, or if you need eye surgery or radiation treatment very soon. Also, if you have other serious eye conditions that might make it difficult to understand the study results, or any other serious health issue that your doctor believes would make taking part unsafe, you wouldn't be able to participate.

Finally, if you are pregnant, breastfeeding, or planning to become pregnant during the study or for three months after your last dose of the study medicine, you would not be able to join. This is a common precaution in many medical studies to protect mothers and babies.

If you decide to take part in this study, you would receive the study medicine, satralizumab, or a placebo (a dummy medicine that looks the same but contains no active drug), typically given as an injection under the skin. You wouldn't know which one you are receiving – this helps ensure the study results are fair.

Throughout the study, you would have regular visits to the clinic. These visits will involve various checks to see how you are doing, including eye examinations, blood tests, and discussions about any symptoms you're experiencing. These assessments help the doctors monitor your health, how the medicine is affecting you, and if your TED is improving. The total time you would be involved in the study would depend on the study's design, including how long the treatment period is and any follow-up appointments after your last dose of medication.